INVESTIGATIONAL NEW DRUGS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2024-01-02 ms4000001640011867 来自福建省

偏重的研究方向：肿瘤;药物
经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗

14 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-08-11 ms1000000639469053 来自广东省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;药物
经验分享：23.5.1日投的稿
23.5.4 同行评审
23.6.12 返回意见
23.6.18 修回
23.6.21 接受
23.7.9 版权和APC问题
23.7.12 Pubmed 检索到

审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。

31 0

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-08-09 ms1000001764947106 来自内蒙古

请问案例报道可以投吗？

25 0

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2020-08-02 1424056585

审稿速度:2.0 | 投稿命中率:50.0
经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…#肿瘤#

810 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-12-15 ms5000002035322087 来自重庆

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！

43 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-12-14 yuanp25167257 来自江苏省

编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。

35 0

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-05-29 lin112

这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？

52 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-14 大鸟快跑

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;临床研究
经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。

62 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 Mia

我是写那种格式的摘要比较好？

64 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2178727, encodeId=79f721e872788, content=偏重的研究方向：肿瘤;药物 经验分享：reviewers invited 1 个月了没动静，找不到审稿人会退稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Tue Jan 02 09:44:27 CST 2024, time=2024-01-02, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2152225, encodeId=0ff52152225fc, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：23.5.1日投的稿 23.5.4 同行评审 23.6.12 返回意见 23.6.18 修回 23.6.21 接受 23.7.9 版权和APC问题 23.7.12 Pubmed 检索到 审稿人还是很友好专业的，个人觉得这个杂志1个月能找到审稿人还是很幸运的。接受后半个月没有任何动静，一旦给你发版权后，就很快了。可以选择没有版面费。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ca5448733, createdName=ms1000000639469053, createdTime=Fri Aug 11 09:12:06 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151942, encodeId=d07e215194211, content=请问案例报道可以投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=393e6422350, createdName=ms1000001764947106, createdTime=Wed Aug 09 14:05:45 CST 2023, time=2023-08-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=805722, encodeId=17a3805e22c1, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：六月十五投了篇，在编辑那停留了半个月后就under review，7月14日，外审结束，当晚就给了修稿，修稿意见是这样的：这是篇很不错的文章，总结一下很不错的工作，但存在多处语法的错误，需要对语言进行编辑修改，没让我补实验。收到修稿函后，花了半个月修稿完就提交了。提交后的第二天就从reviews completed 变为Accept 了。编辑挺负责的，总的来说还是挺快的…<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=810, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68e94695506, createdName=1424056585, createdTime=Sun Aug 02 10:34:35 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106157, encodeId=bf59210615e1d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：22年九月初投的稿，已经三个半月了还没外审回来，我真的无语了，看别人的都是一两个月就外审回来，再不外审回来真的生气了！！！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d555680512, createdName=ms5000002035322087, createdTime=Thu Dec 15 10:50:01 CST 2022, time=2022-12-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106034, encodeId=15b42106034f6, content=编辑老师很认真负责，投稿接受修回都很快，让人感觉幸福来的很突然。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee172609672, createdName=yuanp25167257, createdTime=Wed Dec 14 17:00:18 CST 2022, time=2022-12-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223255, encodeId=d479122325552, content=这个杂志邮件通知手稿已经被接收了，但是接下来一周任何操作提示都没有，应该怎么办啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7965534931, createdName=lin112, createdTime=Sun May 29 23:06:38 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079947, encodeId=921810e994758, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;临床研究 经验分享：很不错的期刊，审稿速度，审稿效率都是很不错的。很欢迎上市后的临床研究。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/0A711D2CC5E0F3D07C1F1766E5448576/100, createdBy=6cd12546777, createdName=大鸟快跑, createdTime=Tue Dec 14 14:41:52 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092203, encodeId=b2c4109220373, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092204, encodeId=42dd10922044c, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 学医的彭于晏

摘要一般有什么要求？

60 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务